This book examines the role of genetic toxicology in evaluating the safety of new pharmaceuticals. It covers genotoxicity assays, data interpretation, and regulatory guidelines for assessing the mutagenic and carcinogenic potential of drug candidates. The book emphasizes the integration of genetic toxicology into the drug development pipeline to ensure product safety. Ideal for pharmaceutical scientists and toxicologists, it advances the application of genetic toxicology in creating safe medications.
Dylan Weiss specializes in genetic toxicology in drug development, focusing on testing and analyzing how pharmaceutical compounds may cause genetic damage. His research includes developing protocols for preclinical testing to assess the genotoxicity of new drugs. Dylan advocates for early-stage genetic toxicology testing to reduce the risks of adverse effects in drug development. He educates pharmaceutical scientists on best practices for evaluating genetic toxicity in drug candidates.